A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

Inclusion Criteria

• •1. Able to provide written informed consent (either from patient or patient's legally acceptable representative)
• •2. Male or female patients 21 years of age or older with BMI ≥ 20 to ≤ 40 kg/m2
• •3. Patients with alcoholic hepatitis defined as:
• •1. History of heavy alcohol abuse: \> 40 g/day in females or \> 60 g/day in males for a minimum period of 6 months, AND
• •2. Consumed alcohol within 12 weeks of entry into the study, AND
• •3. Serum bilirubin \> 3 mg/dL AND AST \> ALT, but less than 300 U/L AND
• •4. MELD score between 11-30, inclusive
• •4. No evidence of active infection as determined by the investigator.
• •5. Women of child-bearing potential must utilize appropriate birth control throughout the study duration.
• •6. Male patients must agree to use a medically acceptable method of contraception/birth control throughout the study duration